San Diego-primarily based Viking Therapeutics marked itself as a serious competitor inside the weight loss drug industry in February after revealing promising data from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in March the company unve